Literature DB >> 23255915

Single nucleotide polymorphism array analysis of microsatellite-stable, diploid/near-diploid colorectal carcinomas without the CpG island methylator phenotype.

Michael Linnebacher1, Christiane Ostwald, Dirk Koczan, Tareq Salem, Björn Schneider, Mathias Krohn, Mathias Ernst, Friedrich Prall.   

Abstract

Colorectal carcinomas are considered to progress by chromosomal instability (CIN), or microsatellite instability (MSI) and/or epigenetic gene silencing; however, in previous studies we observed a small fraction of tumours without this molecular phenotype. To further investigate these 'X-type' tumours, neoplastic glands from five tumours were isolated by laser-capture microdissection and used for single nucleotide polymorphism (SNP) array analyses. DNA from our own low-passage primary colorectal carcinoma cell lines (n=9) was used for comparison. Two of these 'X-type' tumours had very low numbers of aberrations (totals of four and five, respectively), consisting of trisomies and arm amplifications. Conversely, aberrations were markedly more frequent in the control cases and three of the 'X-type' tumours (range, 11-40). These aberrations included deletions of chromosomes and chromosome arms, uniparental disomies (UPD), trisomies and arm amplifications. Recurrent microdeletions (<1 MB) were observed at 3p14.2 (FHIT), 16p13.2 (A2BP1) and 20p12.1 (MACROD2). Microsatellite analyses with polymorphic markers at five 'canonical' colorectal carcinoma loci demonstrated a complete loss of one allele in all but one case. When compared to the SNP arrays, concordant results were observed in 93% of tests; however, this was only if DNA from cell lines or laser-capture microdissections was used. In conclusion, colorectal carcinomas may develop without the classic molecular features of CIN, MSI and/or CpG island methylator phenotype (CIMP), but this is a rare event. UPD is frequent but does not define a separate molecular phenotype. Furthermore, our study supports the notion that SNP arrays are reliable for genome-wide detection of deletions and UPD, but discourages the use of microsatellite analyses to detect loss of heterozygosity with DNA from whole tissues.

Entities:  

Year:  2012        PMID: 23255915      PMCID: PMC3525458          DOI: 10.3892/ol.2012.1006

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  18 in total

Review 1.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features.

Authors:  J R Jass
Journal:  Histopathology       Date:  2007-01       Impact factor: 5.087

2.  Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC ) gene.

Authors:  F Prall; V Weirich; C Ostwald
Journal:  Histopathology       Date:  2007-02       Impact factor: 5.087

3.  Frequent genomic loss at chr16p13.2 is associated with poor prognosis in colorectal cancer.

Authors:  Claus Lindbjerg Andersen; Philippe Lamy; Kasper Thorsen; Eigil Kjeldsen; Friedrik Wikman; Palle Villesen; Bodil Øster; Søren Laurberg; Torben Falck Ørntoft
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

4.  CpG island methylator phenotype in colorectal cancer.

Authors:  M Toyota; N Ahuja; M Ohe-Toyota; J G Herman; S B Baylin; J P Issa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.

Authors:  S Ogino; M Cantor; T Kawasaki; M Brahmandam; G J Kirkner; D J Weisenberger; M Campan; P W Laird; M Loda; C S Fuchs
Journal:  Gut       Date:  2006-01-11       Impact factor: 23.059

Review 6.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

7.  Hotspots of large rare deletions in the human genome.

Authors:  W Edward C Bradley; John V Raelson; Daniel Y Dubois; Eric Godin; Hélène Fournier; Charles Privé; René Allard; Vadym Pinchuk; Micheline Lapalme; René J A Paulussen; Abdelmajid Belouchi
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

8.  Cryopreservation of human colorectal carcinomas prior to xenografting.

Authors:  Michael Linnebacher; Claudia Maletzki; Christiane Ostwald; Ulrike Klier; Mathias Krohn; Ernst Klar; Friedrich Prall
Journal:  BMC Cancer       Date:  2010-07-08       Impact factor: 4.430

Review 9.  Genetic instabilities in human cancers.

Authors:  C Lengauer; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

Review 10.  The impact of translocations and gene fusions on cancer causation.

Authors:  Felix Mitelman; Bertil Johansson; Fredrik Mertens
Journal:  Nat Rev Cancer       Date:  2007-03-15       Impact factor: 60.716

View more
  3 in total

Review 1.  Orchestration of neurodevelopmental programs by RBFOX1: implications for autism spectrum disorder.

Authors:  Brent R Bill; Jennifer K Lowe; Christina T Dybuncio; Brent L Fogel
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

2.  ATM induces MacroD2 nuclear export upon DNA damage.

Authors:  Barbara Golia; Giuliana Katharina Moeller; Gytis Jankevicius; Andreas Schmidt; Anna Hegele; Julia Preißer; Mai Ly Tran; Axel Imhof; Gyula Timinszky
Journal:  Nucleic Acids Res       Date:  2016-10-07       Impact factor: 16.971

3.  Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers.

Authors:  Romina Briffa; Inhwa Um; Dana Faratian; Ying Zhou; Arran K Turnbull; Simon P Langdon; David J Harrison
Journal:  PLoS One       Date:  2015-12-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.